Key Takeaways PACB posted a mixed Q3, beating earnings but missing revenue estimates.PACB placed most Revio and Vega systems with new customers, expanding its installed base beyond upgrades.PACB faces longer purchasing cycles as funding constraints delay Revio buying.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong third-quarter results, is expected to contribute further. However, concerns about l ...